Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that CEO Vuong Trieu will present the Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego, highlighting the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications, addressing a critical challenge in drug delivery for poorly soluble compounds.
The companies plan to showcase development progress across multiple Deciparticle programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. These programs aim to improve therapeutic index and reduce toxicity associated with current formulations containing excipients like polysorbate. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI platform, which accelerates research and regulatory processes.
This announcement is significant because it demonstrates a concrete application of nanotechnology combined with AI to solve a longstanding pharmaceutical hurdle: delivering water-insoluble drugs intravenously. Many potent anticancer and immunosuppressive agents are poorly water-soluble, requiring toxic solvents or complex formulations that limit dosing and cause adverse reactions. The Deciparticle platform's ability to form stable sub-20 nm particles could enable safer, more effective administration of such drugs, potentially expanding their clinical utility and patient tolerability.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company leverages its proprietary AI-enabled PDAOAI platform for biomarker discovery and regulatory support, and holds a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline. Sapu Nano develops next-generation nanomedicine platforms to improve drug delivery and unlock new clinical potential for established therapeutics.
The presentation at BIO 2026, one of the largest biotechnology industry events, will provide a platform for the companies to attract potential partners and investors. The integration of AI through PDAOAI into nanomedicine development represents a forward-looking approach that could streamline formulation design and reduce time to clinic for new drug candidates.
